Skip to main content
. 2018 Nov 26;34(5):783–796. doi: 10.1002/jbmr.3606

Figure 2.

Figure 2

Administration of anti‐TGFβ (1D11) in combination with Zol significantly increased BV/TV compared with monotherapy in the JJN3 model of myeloma. (A) Schematic demonstrating the treatment schedule for Zol or 1D11 monotherapies or in combination in the JJN3 model of myeloma. (B) Representative 3D trabecular bone μCT images from the tibias of JJN3 + vehicle (JJN3) (i), JJN3 + Zol (Zol) (ii), JJN3 + 1D11 (1D11) (iii), and JJN3 + 1D11 + Zol (Combo) (iv) mice. BV/TV (v), trabecular number (vi), and trabecular thickness (vii) analyzed in the tibias by μCT. (C) Representative 3D transverse cortical and trabecular bone μCT images from the tibias of JJN3 (i), Zol (ii), 1D11 (iii), and Combo (iv) mice; blue arrows show areas of bone loss and green arrows show areas of new bone formation. Cortical thickness (v), lesion number (vi), and lesion area (vii) analyzed in the tibias by μCT. All data are presented as mean ± SD, one‐way ANOVA and Tukey's multiple comparison test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.